This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top articles covered at the ACC Scientific Session
Click Here to Manage Email Alerts
The ACC Annual Scientific Session is home to some of the most important late- breaking clinical trials presented to some of the world’s leading interventional cardiologists. Cardiology Today’s Intervention has compiled a list of the top studies, presentations and abstracts presented at the meeting this year in Washington, D.C.
This year’s highlights include the 2-year results of the ABSORB III trial, the DECISION-CTO trial, the SURTAVI trial, the COMPARE-ACUTE trial and much more.
ABSORB III 2-year results suggest optimal techniques may be key
At 2 years, the cumulative rate of target lesion failure was higher with a bioresorbable vascular scaffold compared with an everolimus-eluting stent, but the difference was smaller in patients with appropriately sized vessels in the ABSORB III trial.
Patients with HIV may require PCI at younger age
Patients with HIV had an increased risk for CHD and acute MI and may require PCI at a younger age.
PCI, optimal medical therapy yield similar outcomes in DECISION-CTO trial
In the first randomized clinical trial to compare optimal medical therapy alone with PCI in patients with a coronary chronic total occlusion, the therapeutic strategy was noninferior to intervention for the primary endpoint of death, MI, stroke or any revascularization at 3 years.
iFR noninferior to FFR for revascularization in patients with stable angina, ACS
At 1 year, rates of MACE in patients who underwent revascularization guided by instantaneous wave-free ratio were comparable to those in patients who underwent revascularization guided by fractional flow reserve, according to data from two studies presented.
TAVR in bicuspid aortic stenosis more effective with newer-generation devices
Treatment of bicuspid aortic stenosis with transcatheter aortic valve replacement was comparable to transcatheter aortic valve replacement in tricuspid aortic stenosis, but the procedure was more successful with newer-generation systems.
EXCEL: PCI may be acceptable in patients with diabetes, less complex left main CAD
Three-year data from the EXCEL trial indicate that PCI with an everolimus-eluting stent may be acceptable or even preferable to CABG for treatment of patients with diabetes, left main coronary artery disease and a low to intermediate SYNTAX score.
Same-day discharge may be safe after PCI for non-ST-elevation ACS
Same-day discharge after PCI for non-ST-elevation ACS was not associated with adverse outcomes after 30 days.
COMPARE-ACUTE: FFR-guided complete revascularization linked to lower risk for adverse events
In patients with STEMI and multivessel disease, complete revascularization guided by fractional flow reserve was associated with reduced adverse events compared with PCI of an infarct-related artery only, according to data presented by Pieter Smits, MD, PhD.
SURTAVI: TAVR noninferior to surgery in intermediate-risk patients
The SURTAVI trial met its primary endpoint demonstrating that transcatheter aortic valve replacement with a self-expanding bioprosthesis was comparable to surgery for all-cause mortality or disabling stroke at 24 months, Michael J. Reardon, MD, reported.
Hemodynamic support system improves survival in acute MI, cardiogenic shock
Use of a percutaneous heart pump for hemodynamic support before PCI in patients with acute MI and cardiogenic shock appears to improve survival.